Logo.png
Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight
March 25, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be...
Global Market for Human Liver Models
Global Human Liver Models Market to 2028: Featuring Ascendance Biotechnology, CN Bio Innovations, Cyfuse Biomedical, Emulate and Organovo Holdings Among Others
February 21, 2023 13:03 ET | Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Human Liver Models - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Liver...
TIP_link_300x300.jpg
Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners
May 04, 2022 08:37 ET | The Insight Partners
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Inventiva announces
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
October 18, 2021 16:00 ET | INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Inventiva annonce la
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
October 18, 2021 16:00 ET | INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
Akero logo with white space 1.jpg
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
March 22, 2021 16:01 ET | Akero Therapeutics
-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution -- --...
Akero logo with white space 1.jpg
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
March 22, 2021 06:30 ET | Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Global Liver Institute Offering Multilingual Materials and Grants for International NASH Day on June 10
March 04, 2021 09:24 ET | Global Liver Institute
Washington, DC, March 04, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) is pleased to announce that the 2021 International NASH Day (#NASHday) will be held on June 10, 2021, with the theme,...
Surrozen Logo FINAL Large-1.png
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
October 15, 2020 07:00 ET | Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...
Surrozen Logo FINAL Large-1.png
Surrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports
August 19, 2020 10:00 ET | Surrozen, Inc.
 -- Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc.,...